Inflammatory Pseudotumor/Inflammatory Myofibroblastic Tumor of Spleen – A Case Report
DOI:
https://doi.org/10.3889/oamjms.2020.3901Keywords:
Inflammatory pseudotumor, Inflammatory myofibroblastic tumor, Spleen, Immunohistochemistry, Next-generation sequencingAbstract
BACKGROUND: Splenic inflammatory pseudotumor (IPT)/inflammatory myofibroblastic tumor (IMT) is a rare pseudotumor/tumor of unknown origin, which is usually benign, although atypical and aggressive cases have been reported. It is a lesion composed of proliferated myofibroblastic cells (hence IMT by some authors) with admixed pleomorphic inflammatory cells of varying proportions.
CASE REPORT: Herein, we report a case of 61-year-old male patient with ill-defined abdominal discomfort and no other symptoms and signs. Clinical and imaging investigations revealed a mass in the spleen that was equivocally interpreted as secondary neoplasm, although primary neoplasm of the spleen was not excluded by the radiologists. Splenectomy was performed and on gross examination a well demarcated greyish-livid tumor measuring 3.5 cm × 3 cm × 3 cm was discovered. Microscopic examination showed proliferation of loosely arranged spindle cells admixed with inflammatory cells (histiocytes, lymphocytes, neutrophils, eosinophils, occasional plasma cells, and/or plasmacytoid cells) with varying density and multifocal clustering, multifocal hemorrhage, and fibrinoid-like deposition. We performed additional histochemical and immunohistochemical stainings which were consistent with the diagnosis of IPT/IMT. Next-generation sequencing (TruSight Tumor 15) showed common TP53 polymorphism (c.215C>G; p.Pro72Arg) along with several intronic and synonymous single nucleotide variations (SNVs), as well as five low confidence missense SNVs. Sixteen months after the operation the patient has uneventful follow-up.
CONCLUSION: Although the incidence of IPT/IMT is low, awareness of its existence is necessary. The prognosis is favorable following splenectomy in most cases. Careful microscopic examination of the specimen is mandatory, due to possible misdiagnosis. We believe that extensive NGS analysis on archive samples would provide more data about the spectrum of possible genetic changes in lesions like IPM/IMT.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Cotelingam JD, Jaffe ES. Inflammatory pseudotumor of the spleen. Am J Surg Pathol. 1984;8(5):375-80. PMid:6329007
Neuhauser TS, Derringer GA, Thompson LD, FanburgSmith JC, Aguilera NS, Andriko J, et al. Splenic inflammatory myofibroblastic tumor (inflammatory pseudotumor): A clinicopathologic and immunophenotypic study of 12 cases. Arch Pathol Lab Med. 2001;125(3):379-85. PMid:11231487
Ma ZH, Tijan XF, Ma J, Zhao YF. Inflammatory pseudotumor of the spleen: A case report and review of published cases. Oncol Lett. 2013;5(6):1955-7. https://doi.org/10.3892/ol.2013.1286 PMid:23833674
McMahon G, Rady K, Prince MH. Inflammatory pseudotumor of the spleen. Hematol Rep. 2015;7(2):5905. https://doi. org/10.4081/hr.2015.5905 PMid:26331003
Ugalde P, Bernardo CG, Granero P, Miyar A, González C, González-Pinto I, et al. Inflammatory pseudotumor of spleen: A case report. Int J Surg Case Rep. 2015;7C:145-8. PMid:25648471
Toumi O, Ammar H, Chhaidar A, Gupta R, Korbi I, Nasr M, et al. Inflammatory pseudotumor of spleen: A case report. Arch Clin Med Case Rep. 2017;1(1):31-4. https://doi.org/10.26502/ acmcr.9655006
Gleason CB, Hornick LJ. Inflammatory myofibroblastic tumours: Where are we now? J Clin Pathol. 2008;61(4):428-37. Doi:10.1136/jcp.2007.049387 PMid:17938159
Rajabi P, Noorollahi H, Hani M, Bagheri M. Inflammatory pseudotumor of spleen. Adv Biomed Res. 2014;3:29-38. https:// doi.org/10.4103/2277-9175.124679 PMid:24592376
Kim HJ, Cho HJ, Park SM, Chung HJ, Lee GJ, Kim SY, et al. Pulmonary inflammatory pseudotumor. Korean J Intern Med. 2002;17(4):252-8. PMid:12647641
Kutok JL, Pinkus GS, Dorfman DM, Fletcher CD. Inflammatory pseudotumor of lymph node and spleen: An entity biologically distinct from inflammatory myofibroblastic tumor. Hum Pathol. 2001;32(12):1382-7. https://doi.org/10.1053/hupa.2001.29679 PMid:11774173
Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: Comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol. 2007;31(4):509-20. https://doi.org/10.1097/01. pas.0000213393.57322.c7 PMid:17414097
Davies DK, Villalobos MV, Aisner LD. Ready or not here I come: Inflammatory myofibroblastic tumors with kinase alterations revealed through molecular hide and seek. J Thorac Oncol. 2019;14(5):758-60. https://doi.org/10.1016/j.jtho.2019.02.006 PMid:31027738
Salehinejad J, Pazouki M, Gerayeli MA. Malignant inflammatory myofibroblastic tumor of the maxillary sinus. J Oral Maxillofac Pathol. 2015;17(2):306-10. https://doi. org/10.4103/0973-029x.119754 PMid:24250100
Khanafshar E, Phillipson J, Schammel DP, Minobe L, Cymerman J, Weidner N. Inflammatory myofibroblastic tumor of the breast. Ann Diagn Pathol. 2005;9(3):123-9. https://doi. org/10.1016/j.anndiagpath.2005.02.001 PMid:15944952
Zardawi IM, Clark D, Williamsz G. Inflammatory myofibroblastic tumor of the breast. A case report. Acta Cytol. 2003;47(6):1077- 81. https://doi.org/10.1159/000326651 PMid:14674084
Krings G, McIntire P, Shin SJ. Myofibroblastic, fibroblastic and myoid lesions of the breast. Semin Diagn Pathol. 2017;34(5):427- 37. https://doi.org/10.1053/j.semdp.2017.05.010 PMid:28751104
Zavras N, Poddighe D. Cranial fasciitis of childhood (CFC): An unusual clinical case of a rare disease. BMJ Case Rep. 2017;2017:220859. https://doi.org/10.1136/ bcr-2017-220859 PMid:28903973
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2020 Rubens Jovanovic, Aleksandar Eftimov, Svetozar Antovic, Ognen Kostovski, Bojan Labachevski, Aleksandar Nikodinovski, Gordana Petrushevska (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
